Gastroenterology

Are Probiotics Money Down the Toilet? Or Worse? – JAMA (free for a limited period)

Related: Randomized Trials: Probiotics Ineffective Against Gastroenteritis (link to abstract and commentaries) AND Perspective: The Problem with Probiotics (free commentaries) AND Probiotics: Does the Evidence Match the Hype? (link to abstract and commentaries) AND Systematic Review: Harms Reporting in Trials with Probiotics (link to abstract and commentaries)

 


Thailand Dyspepsia Guidelines

27 Jan, 2019 | 20:11h | UTC

Accelerating the elimination of viral hepatitis – Commissions from the Lancet journals (free articles – registration required)

 

Related Commentary on Twitter

 


Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies – Osteoporosis International (link to abstract – $ for full-text)

Commentary: PPIs up risk for hip fracture in large meta-analysis – Univadis (free registration required)

 

Related Commentary on Twitter


Guideline: Autoimmune Hepatitis

4 Jan, 2019 | 20:09h | UTC

Review: Hepatic Echinococcosis

20 Nov, 2018 | 15:11h | UTC

Pantoprazole in Patients at Risk for Gastrointestinal Bleeding in the ICU – New England Journal of Medicine (free for a limited period)

Editorial: Proton-Pump Inhibitor Prophylaxis in the ICU — Benefits Worth the Risks? (free for a limited period)

“Proton pump inhibitors are minimally effective to reduce GI bleeding among the critically ill folks at high risk for stress ulcers. Takeaways: no role for routine PPI for any patients on the WARDS, and shouldn’t be considered ‘routine’ in the ICU” (via @AnilMakam see Tweet)

 


Review: Diabetic Gastroparesis

16 Oct, 2018 | 21:45h | UTC

Review: Sclerosing Mesenteritis

16 Oct, 2018 | 21:35h | UTC

Report: Global Burden of Diarrhea

21 Sep, 2018 | 02:06h | UTC

Probiotic Safety—No Guarantees – JAMA Internal Medicine (free for a limited period)

Related: Probiotics: Does the Evidence Match the Hype? (free articles and commentaries) AND Systematic Review: Harms Reporting in Trials with Probiotics (link to abstract and commentaries)

 


NICE Guideline: Pancreatitis

14 Sep, 2018 | 01:30h | UTC

Guideline: Intestinal Failure in Adults

31 Aug, 2018 | 01:41h | UTC

Rotavirus Vaccination and the Global Burden of Rotavirus Diarrhea Among Children Younger Than 5 Years – JAMA Pediatrics (free)

“Rotavirus-associated mortality has decreased by 48.2% in children under 5 between 1990 and 2016” (via @IHME_UW see Tweet with infographics)

 


Guideline: Primary Biliary Cholangitis

11 Aug, 2018 | 02:23h | UTC

Review: Elevation of Liver Enzymes

11 Aug, 2018 | 02:17h | UTC

Review: The Brain-Gut-Microbiome Axis

26 Jul, 2018 | 17:41h | UTC

Review: Pancreatic Cystic Lesions

22 Jun, 2018 | 02:10h | UTC

Review: Secondary Peritonitis

18 Jun, 2018 | 23:21h | UTC

A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis – New England Journal of Medicine (link to abstract – $ for full-text)

Commentaries: A Trial of Bezafibrate in Primary Biliary Cholangitis – NEJM Resident 360 (free) AND Bezafibrate Normalizes Liver Enzymes in PBC – MedPage Today (free registration required)

“In a randomized trial of patients with primary biliary cholangitis, bezafibrate and ursodeoxycholic acid resulted in a higher rate of complete biochemical response than ursodeoxycholic acid alone” (via @NEJM see Tweet with visual abstract)

 


Review: Surgery for Metastatic GISTs

3 May, 2018 | 19:20h | UTC

Pancreatitis: Pearls & Pitfalls

23 Apr, 2018 | 20:59h | UTC

Acid‐suppressive drugs and risk of kidney disease: A systematic review and meta‐analysis – Journal of Gastroenterology and Hepatology (link to abstract – $ for full-text)

Source: Hospital Medicine Virtual Journal Club

Proton pump inhibitors were associated with higher risks of acute interstitial nephritis (HR, 2.78; 95% CI, 1.25‐6.17), acute kidney injury (HR, 1.85; 95% CI, 1.33‐2.59), chronic kidney disease (HR, 1.47; 95% CI, 1.03‐2.09), and end‐stage renal disease (HR, 1.61; 95% CI, 1.26‐2.04) than non‐PPI therapy. Similar risks were not identified for H2RA therapy.

 


Guideline: treatment of Hepatitis C

12 Apr, 2018 | 02:42h | UTC

Guideline: irritable bowel syndrome

6 Apr, 2018 | 01:07h | UTC